Aromatase inhibitors may replace tamoxifen
LOS ANGELES, CALIF., April 8, 2004 -- A four-year update of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial shows that patients on anastrozole have longer disease-free survival, lower incidence of contralateral breast cancer, and fewer side effects than women taking tamoxifen.
Two other aromatase inhibitors, letrozole and exemestane, are also proving more effective than tamoxifen. "In metastatic disease, and possibly in the adjuvant setting as well, it appears that the aromatase inhibitors will replace tamoxifen, at least for postmenopausal women," says Lawrence Wickerham, MD, Associate Chairman, National Surgical Adjuvant Breast and Bowel Project (NSABP), and associate professor of human oncology at Drexel University in Pittsburgh, PA.
John Link, MD, founder of The Breast Cancer Care & Research Fund, says: "Never has there been a more exciting or hopeful time for breast cancer research and treatment. We are beginning to understand this disease at the molecular and genetic levels. More treatment options are available. Women need to become informed so they can advocate for themselves and actively participate in obtaining optimal treatment for their particular breast cancer."
Breastlink.org is supported totally by the Breast Cancer Care & Research Fund (BCCRF), a publicly supported, nonprofit 501(C) (3) organization. Consumer privacy is ensured, as the site does not collect information or require registration to enter or navigate. For more information, see www.breastlink.org or contact The Breast Cancer Care & Research Fund, Mary Batten, Editor-in-Chief, 12400 Wilshire Blvd., Suite 200, Los Angeles, CA, 90025. Phone: 310-207-0209 e-mail: firstname.lastname@example.org
Source: Breastlink www.breastlink.org
Posted: April 2004